Voyager Therapeutics Inc

For the period ended Dec 31, 2024. Filed Mar 11, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 11, 2025

VYGR$1.83-8.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

(amounts in thousands)


· · Year ended ·
· · December 31,
· 2024 · 2023 · 2022
Cash flow from operating activities · · · · · · ·
Net (loss) income	$(65,002)	$132,330	$(46,408)
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Stock-based compensation expense	14,785	11,153	9,344
Depreciation	4,731	4,441	6,191
Amortization of premiums and discounts on marketable securities	(7,969)	(3,626)	(16)
Impairment charge on leased facility	2,776	—	—
Gain on lease termination	—	—	(2,468)
Loss on disposal of fixed assets	510	178	377
Changes in operating assets and liabilities:
Accounts receivable	78,646	(80,150)	—
Related party collaboration receivable	2,665	(3,084)	475
Prepaid expenses and other assets	(2,627)	76	(1,967)
Operating lease, right-of-use assets	4,597	1,975	3,462
Other non-current assets	—	—	(152)
Accounts payable	2,392	(962)	1,992
Accrued expenses	(2,652)	9,007	(3,148)
Operating lease liabilities	(3,320)	(2,833)	(3,922)
Deferred revenue	(44,842)	9,414	23,731
Net cash (used in) provided by operating activities	(15,310)	77,919	(12,509)
Cash flow from investing activities
Purchases of property and equipment	(3,521)	(3,256)	(2,491)
Purchases of marketable securities	(465,685)	(223,968)	(54,848)
Proceeds from sales and maturities of marketable securities	374,347	85,581	50,000
Net cash used in investing activities	(94,859)	(141,643)	(7,339)
Cash flow from financing activities
Proceeds from the exercise of stock options	388	1,852	629
Proceeds from the issuance of common stock in connection with the underwritten public offering	93,473	—	—
Proceeds from the issuance of common stock in connection with the 2023 Novartis Stock Purchase Agreement	19,305	—	—
Proceeds from the issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement	—	31,121	—
Proceeds from the purchase of common stock under ESPP	849	672	481
Net cash provided by financing activities	114,015	33,645	1,110
Net increase (decrease) in cash, cash equivalents, and restricted cash	3,846	(30,079)	(18,738)
Cash, cash equivalents, and restricted cash beginning of period	70,395	100,474	119,212
Cash, cash equivalents, and restricted cash end of period	$74,241	$70,395	$100,474
Supplemental disclosure of cash and non-cash activities
Operating lease right-of-use asset obtained in exchange for operating lease liability	$26,751	$—	$—
Capital expenditures incurred but not yet paid	$—	$—	$14

VOYAGER THERAPEUTICS INC.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.